Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

219.96
-1.5300-0.69%
Volume:1.22M
Turnover:266.51M
Market Cap:13.57B
PE:-48.47
High:222.99
Open:211.00
Low:211.00
Close:221.49
52wk High:242.00
52wk Low:118.03
Shares:61.70M
Float Shares:60.08M
Volume Ratio:1.44
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5384
EPS(LYR):-6.7615
ROE:-818.43%
ROA:-7.69%
PB:-65.67
PE(LYR):-32.53

Loading ...

Ascendis Pharma Shows Steady Progress Toward Long-Term Growth, Wedbush Says

MT Newswires Live
·
3 hours ago

Ascendis Pharma Is Maintained at Outperform by Wedbush

Dow Jones
·
Yesterday

Wedbush Raises Price Target on Ascendis Pharma to $273 From $240, Keeps Outperform Rating

MT Newswires Live
·
Yesterday

Ascendis Pharma a/S : Oppenheimer Raises Target Price to $262 From $246

THOMSON REUTERS
·
Yesterday

RBC Capital Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Yesterday

Ascendis Pharma a/S : Stifel Raises Target Price to $325 From $256

THOMSON REUTERS
·
Yesterday

ASND: Strong Yorvipath Momentum and Pipeline Catalysts Underpin Buy Rating and Long‑Term Upside

TIPRANKS
·
Yesterday

Teijin Pharma Applies for Japanese Approval of Weekly Pediatric Growth Hormone Treatment

Reuters
·
Yesterday

Earnings Flash (ASND) Ascendis Pharma Posts Q4 Loss -0.55 Euro, vs. FactSet Est of -0.19 Euro Loss

MT Newswires Live
·
Yesterday

Ascendis Pharma Q4 EPS $(0.64) Misses $(0.06) Estimate, Sales $288.127M Miss $289.720M Estimate

Benzinga
·
Yesterday

Ascendis Pharma reports FY 2025 net loss of EUR 228 million, narrowing 40%

Reuters
·
Yesterday

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 11

Health Canada genehmigt Yorvipath von Ascendis Pharma für die Behandlung von chronischem Hypoparathyreoidismus

Reuters
·
Feb 07

Ascendis Pharma A/S to Announce Full Year 2025 Financial Results and Business Update

Reuters
·
Feb 05

Ascendis Pharma price target raised to $260 from $246 at BofA

TIPRANKS
·
Jan 30

Ascendis Pharma Is Maintained at Buy by B of A Securities

Dow Jones
·
Jan 30

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading

MT Newswires Live
·
Jan 29

Ascendis Pharma Initiated at Overweight by Barclays

Dow Jones
·
Jan 28

Barclays Initiates Coverage on Ascendis Pharma With Overweight Rating, $342 Price Target

MT Newswires Live
·
Jan 28

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
Jan 27